Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...

Telehealth firm Hims & Hers Health Inc. (HIMS) reported strong first-quarter 2025 results, with revenue more than doubling ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Users of Ozempic say it quietens their food noise - I've got the same effect from a £99 meditation app In late February, for the first time in my adult life, I walked around the supermarket without an ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Weight loss medications and bariatric surgery used to be considered last-resort options, but now, they’re everywhere. More ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...